InMed Announces Management Changes
March 17 2022 - 6:30AM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM), a leader in the research, development,
manufacturing and commercialization of rare cannabinoids, today
announces that its Chief Financial Officer, Mr. Bruce Colwill, will
be retiring and will be stepping down from his position at the
Company effective March 31, 2022. Mr. Colwill will continue to
serve as an advisor through June 30, 2022 to facilitate a smooth
transition.
Ms. Brenda Edwards has been appointed as Interim
Chief Financial Officer of the Company effective April 1, 2022. The
Company has initiated a search for a full time replacement.
Ms. Edwards brings over 35 years experience to
InMed including over 20 years as a Chief Financial Officer of both
private and public companies. Her experience includes merger and
acquisitions, financings, managing high growth situations and
financial reporting. She is a member of both the American Institute
of CPAs and the Chartered Professional Accountants of Canada.
Eric A. Adams, InMed President and Chief
Executive Officer, commented; “I would like to thank Bruce for
his invaluable leadership and significant contributions over almost
three years including managing our transition to the Nasdaq and
several financings to ensure the long-term growth of the Company. I
wish him the very best and appreciate his continued assistance to
ensure a smooth transition.” He continued, “I am delighted to
welcome Brenda to the Company. Brenda comes with extensive
experience and will be an excellent fit to help us through this
transitional period.”
About InMed: InMed
Pharmaceuticals is a global leader in the research, development,
manufacturing and commercialization of rare cannabinoids. Together
with its subsidiary BayMedica LLC, the Company has unparalleled
cannabinoid manufacturing capabilities to serve a spectrum of
consumer markets, including pharmaceutical and health and wellness.
InMed is also a clinical-stage company developing a pipeline of
rare cannabinoid therapeutics and dedicated to delivering new
treatment alternatives to patients that may benefit from
cannabinoid-based pharmaceutical drugs. For more information,
visit www.inmedpharma.com and www.baymedica.com.
Investor Contact: Colin ClancySenior Director,
Investor RelationsT: +1.604.416.0999E: cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about; being a global leader in the research,
development, manufacturing and development of rare cannabinoids;
having unparalleled cannabinoid manufacturing capabilities to serve
a spectrum of consumer markets, including pharmaceutical and health
and wellness; about Ms. Edwards being appointed Interim Chief
Financial Officer of the Company effective April 1, 2022; and,
developing a pipeline of rare cannabinoid therapeutics and
dedicated to delivering new treatment alternatives to patients that
may benefit from cannabinoid-based pharmaceutical drugs.
With respect to the forward-looking information
contained in this news release, InMed has made numerous
assumptions. While InMed considers these assumptions to be
reasonable, these assumptions are inherently subject to significant
business, economic, competitive, market and social uncertainties
and contingencies.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein. A complete discussion
of the risks and uncertainties facing InMed’s stand-alone business
is disclosed in InMed’s Annual Report on Form 10-K and other
filings with the Security and Exchange Commission on
www.sec.gov.
All forward-looking information herein is
qualified in its entirety by this cautionary statement, and InMed
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Mar 2024 to Apr 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Apr 2023 to Apr 2024